NeoNeuro has received support from BPI France under the PIA-1 program to advance the use of aptamers as diagnostic and therapeutic tools for Alzheimer’s disease. This funding allows our team to accelerate the discovery and refinement of aptamers capable of detecting disease-associated biomarkers in blood with high precision. It also supports research into aptamers’ potential as targeted therapies, aiming to develop innovative approaches to slow or treat Alzheimer’s disease. Through this program, NeoNeuro strengthens its commitment to creating minimally invasive, highly accurate solutions for early diagnosis and improved patient outcomes.